The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
VSIG‐3 as a ligand of VISTA inhibits human T‐cell function
Open accessAbstract
Summary: B7 family members and their receptors play a central role in the regulation of T‐cell responses through T‐cell co‐stimulation and co‐inhibition pathways that constitute attractive targets for the development of immunotherapeutic drugs. In this study, we report that VSIG‐3/IGSF 11 is a ligand of B7 family member VISTA/PD‐1H and inhibits human T‐cell functions through a novel VSIG‐3/VISTA pathway. An extensive functional ELISA binding screening assay reveals that VSIG‐3 binds to the new B7 family member VISTA but does not interact with other known members of the B7 family. Under the same experimental conditions, we did not observe any significant interaction between VSIG‐8 and VISTA. In addition, VSIG‐3 inhibits human T‐cell proliferation in the presence of T‐cell receptor signaling. Furthermore, VSIG‐3 significantly reduces cytokine and chemokine production by human T cells including IFN‐γ, IL‐2, IL‐17, CCL 5/Rantes, CCL 3/MIP‐1 α, and CXCL 11/I‐TAC. Anti‐VISTA neutralization antibodies attenuate the binding of VSIG‐3 and VISTA, as well as VSIG‐3‐induced T‐cell inhibition. Hence, we have identified a novel ligand for VISTA that is able to inhibit human T‐cell proliferation and cytokine production. This unique VSIG‐3/VISTA co‐inhibitory pathway may provide new strategies for the treatment of human cancers, autoimmune disorders, infection, and transplant rejection and may aid in the design of better vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,041
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Wang, L., Rubinstein, R., Lines, J. L., Wasiuk, A., Ahonen, C., Guo, Y., Lu, L.-F., Gondek, D., Wang, Y., Fava, R. A., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100619 · Cited by 710
VISTA Regulates the Development of Protective Antitumor Immunity
Le Mercier, I., Chen, W., Lines, J. L., Day, M., Li, J., Sergent, P., Noelle, R. J., & Wang, L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1506 · Cited by 486
Self-citationMa, W., Gilligan, B. M., Yuan, J., & Li, T. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0277-y · Cited by 327
Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell–mediated immunity
Flies, D. B., Han, X., Higuchi, T., Zheng, L., Sun, J., Ye, J. J., & Chen, L. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74589 · Cited by 282
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy
Lines, J. L., Sempere, L. F., Broughton, T., Wang, L., & Noelle, R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0072 · Cited by 236
Lebre, M. C., Burwell, T., Vieira, P. L., Lora, J., Coyle, A. J., Kapsenberg, M. L., Clausen, B. E., & De Jong, E. C. (2005) · Immunology & Cell Biology · doi:10.1111/j.1440-1711.2005.01365.x · Cited by 113
Watanabe, T., Suda, T., Tsunoda, T., Uchida, N., Ura, K., Kato, T., Hasegawa, S., Satoh, S., Ohgi, S., Tahara, H., et al. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2005.00073.x · Cited by 64
Cited by
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Qin, S., Xu, L., Yi, M., Yu, S., Wu, K., & Luo, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1091-2 · Cited by 1,145
VISTA is an acidic pH-selective ligand for PSGL-1
Johnston, R. J., Su, L. J., Pinckney, J., Critton, D., Boyer, E., Krishnakumar, A., Corbett, M., Rankin, A. L., Dibella, R., Campbell, L., et al. (2019) · Nature · doi:10.1038/s41586-019-1674-5 · Cited by 402
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
Saleh, R., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.017 · Cited by 292
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Barrueto, L., Caminero, F., Cash, L., Makris, C., Lamichhane, P., & Deshmukh, R. R. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.12.010 · Cited by 281
Metadata
- Authors
- Wang, J., Wu, G., Manick, B., Hernandez, V., Renelt, M., Erickson, C., Guan, J., Singh, R., Rollins, S., Solorz, A., Bi, M., Li, J., Grabowski, D., Dirkx, J., Tracy, C., Stuart, T., Ellinghuysen, C., Desmond, D., Foster, C., & Kalabokis, V.
- Venue
- Immunology
- Publisher
- Wiley
- Published
- 2018-10-10
- Volume
- 156
- Issue
- 1
- Pages
- 74-85
- ISSN
- 0019-2805 (ISSN-L)
- 1365-2567
- OpenAlex
- W2890463012
- Cited by
- 263
- References
- 16
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: VSIG‐3 as a ligand of VISTA inhibits human T‐cell function. https://app.cochat.ai/papers/10.1111/imm.13001
- The paper
- Wang, J., Wu, G., Manick, B., Hernandez, V., Renelt, M., Erickson, C., Guan, J., Singh, R., Rollins, S., Solorz, A., Bi, M., Li, J., Grabowski, D., Dirkx, J., Tracy, C., Stuart, T., Ellinghuysen, C., Desmond, D., Foster, C., & Kalabokis, V. (2019). VSIG‐3 as a ligand of VISTA inhibits human T‐cell function. Immunology. https://doi.org/10.1111/imm.13001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.